FOXD3 regulates anaplastic thyroid cancer progression

Anaplastic thyroid cancer (ATC) is an aggressive malignancy with poor prognosis. It was reported that Forkhead box D3 (FOXD3) transcription factor is associated with several cancers. We investigated its antitumorigenic role of ATC in this study. The ATC cell lines SW1736 and K18 exhibited lower FOXD3 expression than the Nthy-ori-3-1 normal thyroid cell line. FOXD3 downregulation in ATC cell lines promoted invasiveness and epithelial-to-mesenchymal transition (EMT) and decreased cellular apoptosis. FOXD3 silencing also enhanced p-ERK levels in the ATC cell lines, suggesting it negatively regulated MAPK/ERK signaling. Silencing FOXD3 in SW1736 cells also led to generation of larger xenograft tumors with high p-ERK and low E-cadherin levels. Moreover, human ATC samples showed lower FOXD3 and higher p-ERK levels than samples of normal thyroid tissue. These findings demonstrate that FOXD3 acts as a tumor suppressor during anaplastic thyroid carcinogenesis and highlight its potential for clinical application.

[1]  Min Zhang,et al.  Human biliverdin reductase promotes EMT through the ERK1/2 signal pathway in breast cancer. , 2016, European journal of pharmacology.

[2]  F. Han,et al.  FOXO4 and FOXD3 are predictive of prognosis in gastric carcinoma patients , 2016, Oncotarget.

[3]  Xiaoping Zhou,et al.  FOXD3 suppresses tumor growth and angiogenesis in non-small cell lung cancer. , 2015, Biochemical and biophysical research communications.

[4]  W. Du,et al.  Decreased FOXD3 Expression Is Associated with Poor Prognosis in Patients with High-Grade Gliomas , 2015, PloS one.

[5]  A. Aplin,et al.  FOXD3 Modulates Migration through Direct Transcriptional Repression of TWIST1 in Melanoma , 2014, Molecular Cancer Research.

[6]  J. Yun,et al.  FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2 , 2014, Oncotarget.

[7]  Xuan Sun,et al.  FoxD3 deficiency promotes breast cancer progression by induction of epithelial-mesenchymal transition. , 2014, Biochemical and biophysical research communications.

[8]  Yongxiang Yin,et al.  Downregulation of the transcription factor, FoxD3, is associated with lymph node metastases in invasive ductal carcinomas of the breast. , 2014, International journal of clinical and experimental pathology.

[9]  Kai Huang,et al.  FOXD3 is a novel tumor suppressor that affects growth, invasion, metastasis and angiogenesis of neuroblastoma , 2013, Oncotarget.

[10]  V. D. Di Crescenzo,et al.  Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review , 2013, BMC Surgery.

[11]  M. Xing,et al.  Molecular pathogenesis and mechanisms of thyroid cancer , 2013, Nature Reviews Cancer.

[12]  K. Bible,et al.  Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches , 2011, Expert opinion on investigational drugs.

[13]  A. Aplin,et al.  FOXD3 Regulates Migration Properties and Rnd3 Expression in Melanoma Cells , 2011, Molecular Cancer Research.

[14]  M. Todaro,et al.  Tumorigenic and metastatic activity of human thyroid cancer stem cells. , 2010, Cancer research.

[15]  A. Aplin,et al.  FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells. , 2010, Cancer research.

[16]  M. Shah,et al.  Review: Thyroid cancer: emerging role for targeted therapies , 2010, Therapeutic advances in medical oncology.

[17]  B. Nelkin,et al.  Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. , 2009, The Journal of clinical endocrinology and metabolism.

[18]  J. Copland,et al.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. , 2008, Endocrine-related cancer.

[19]  Pei-Wen Wang,et al.  Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan. , 2004, Thyroid : official journal of the American Thyroid Association.

[20]  M. Goulding,et al.  The winged-helix transcription factor Foxd3 suppresses interneuron differentiation and promotes neural crest cell fate. , 2001, Development.

[21]  A. Müller,et al.  FoxD3 is a novel, epigenetically regulated tumor suppressor in gastric carcinogenesis. , 2013, Gastroenterology.

[22]  Jun Yu,et al.  Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis. , 2013, Gastroenterology.

[23]  D. Goldenberg,et al.  Molecular and genetic markers of follicular-cell thyroid cancer: etiology and diagnostic and therapeutic opportunities. , 2013, Advances in experimental medicine and biology.